The FLORA study: presenting a novel IPF trial design

Affiliations

¹ Service de Pneumologie A, Centre de Reference Constitutif des Maladies Pulmonaires Rares de l'Adulte, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, 75018 Paris, France; INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France. Electronic address: bruno.crestani@aphp.fr.
² Center for Rare and Interstitial Lung Diseases, Justus-Liebig-University Giessen, Giessen, Germany; Lung Clinic Waldhof-Elgershausen, Greifenstein, Germany.

Comment

Bruno Crestani et al. Lancet Respir Med. 2018 Aug.

. 2018 Aug;6(8):572-573.

doi: 10.1016/S2213-2600(18)30269-8. Epub 2018 Jun 27.

¹ Service de Pneumologie A, Centre de Reference Constitutif des Maladies Pulmonaires Rares de l'Adulte, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, 75018 Paris, France; INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France. Electronic address: bruno.crestani@aphp.fr.
² Center for Rare and Interstitial Lung Diseases, Justus-Liebig-University Giessen, Giessen, Germany; Lung Clinic Waldhof-Elgershausen, Greifenstein, Germany.

No abstract available

Comment on

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.
Maher TM, van der Aar EM, Van de Steen O, Allamassey L, Desrivot J, Dupont S, Fagard L, Ford P, Fieuw A, Wuyts W. Maher TM, et al. Lancet Respir Med. 2018 Aug;6(8):627-635. doi: 10.1016/S2213-2600(18)30181-4. Epub 2018 May 20. Lancet Respir Med. 2018. PMID: 29792287 Clinical Trial.